Jump to content

Angiomotin

From Wikipedia, the free encyclopedia
AMOT
Identifiers
AliasesAMOT, angiomotin
External IDsOMIM: 300410; MGI: 108440; HomoloGene: 15778; GeneCards: AMOT; OMA:AMOT - orthologs
Orthologs
SpeciesHumanMouse
Entrez

154796

27494

Ensembl

n/a

ENSMUSG00000041688

UniProt

Q4VCS5

Q8VHG2

RefSeq (mRNA)

NM_001113490
NM_133265
NM_001386998
NM_001386999

NM_001290274
NM_153319

RefSeq (protein)

NP_001106962
NP_573572

Location (UCSC)n/aChr X: 144.23 – 144.29 Mb
PubMed search[2][3]
Wikidata
View/Edit HumanView/Edit Mouse

Angiomotin (AMOT) is a protein that in humans is encoded by the AMOT gene.[4][5][6][7] It belongs to the motin family of angiostatin binding proteins, which includes angiomotin, angiomotin-like 1 (AMOTL1) and angiomotin-like 2 (AMOTL2) characterized by coiled-coil domains at N-terminus and consensus PDZ-binding domain at the C-terminus.[6] Angiomotin is expressed predominantly in endothelial cells of capillaries as well as angiogenic tissues such as placenta and solid tumor.[8]

Discovery

[edit]

Angiomotin was discovered in 2001 by screening a placenta yeast two-hybrid cDNA library for angiostatin-binding peptides, using a construct encoding the kringle domains 1-4 of angiostatin.[4]

Gene location

[edit]

AMOT gene is located on human chromosome X:112,021,794-112,066,354, containing 3252 nucleotides in coding sequence as 11 exons.[9]

Protein structure

[edit]

Two splice isoforms are known for angiomotin: p80 and p130. The alternative splicing is somewhat tissue specific. Cells expressing p130 contained more actin than those expressing p80. p80 is not the product of cleavage of p130, as p130 contains no potential proteolytic cleavage site for such conversion.[10]

Angiomotin p80 is a 72.54 kD protein of 675 residues,[11] characterized by conserved N-terminal coiled coil domains and C-terminal PDZ binding motifs, with angiostatin binding domain (ABD) located in the central region. It is hypothesized that the ABD is extracellular, while the coiled-coil and the PDZ binding domain are intracellular.[5] The PDZ-binding motif of angiomotin serves as a protein recognition site and deletion of as few as three amino acids from the C-terminal results in complete loss of pro-migratory activity, and endothelial cells expressing such mutant angiomotin failed to migrate or form tubes.[12]

Angiomotin p130 differs from p80 by having an N-terminal cytoplasmic extension of 409 amino acids rich in glutamine, which mediates the binding of p130 to F-actin and tight cell-cell junctions. This binding remains after destabilizing actin with cytochalasin B.[10]

Like other surface-associated proteins that can bind plasminogen and its derivatives, angiomotin does not appear to have a signal sequence, thus its association with the cell surface may be via protein–protein interaction usually referred to as non-classic secretion.[8]

Function

[edit]

Role in cell motility and angiogenesis

[edit]

Expression of angiomotin p80 in endothelial cells increases the random migration of endothelial cells, as well as the migration of endothelial cells toward growth factors, e.g. bFGF, VEGF and LPA etc. Angiomotin also mediates tube formation of endothelial cells.[4][12] Angiomotin promotes angiogenesis by both stimulating cell spreading and stabilizing established tubes, e.g. in mouse aortic endothelial (MAE) cells the tubes remained stable for over 30 days, while control tubes started to regress after 3 days.[13] In the presence of angiostatin, endothelial cells expressing angiomotin p80 exhibit reduction in migration as well as reduction in tubules formation in vitro. These observations are consistent with the localization of angiomotin in the leading edge of migrating cells. Angiostatin therefore, is an inhibitor of angiomotin.

Angiomotin p80 locates and binds angiostatin on the cell surface. In primary endothelial of Chinese hamster ovary, it localizes to cell-cell junction, recruits ZO-1 and interacts with MAGI-1. It may play a role in the assembly of endothelial cell-cell junctions, as well.[5]

Angiomotin p130 does not promote cell migration, nor responds to angiostatin. It localizes to cell-cell junction like p80 and regulates paracellular permeability. Its N-terminal domain localizes to actin fibers and stabilizes them, and this effect is not affected by angiostatin. Transfection of p130 angiomotin into MAE cells results in change in cell shape, increased average cell size and stress fiber formation. So p80 is involved in cell migration and expressed during migratory phase. While p130 controls cell shape by interaction with actin, and is expressed during the period of blood vessel stabilization and maturation.[10][14] The relative expression levels of p80 and p130 regulate a switch between a migratory and a non-migratory cell phenotype, where homo-oligomerization of p80 and hetero-oligomerization of both isoforms are critical for this regulation.[14]

Role in Hippo signaling pathway

[edit]

AMOT, AMOTL1 and AMOTL2 play critical roles in the Hippo signaling pathway by regulating the subcellular localization of the co-activators YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif),[15] and activating LATS2 through a novel conserved domain.[16] The activity of YAP and TAZ can be restricted through their interaction with AMOT and AMOTL1, and such interaction depends on the WW domain of TAZ and the Proline-Proline-x–Tyrosine motif at the N-terminus of AMOT.[17]

In position-dependent Hippo signaling, where the outer and inner cells are polar and nonpolar respectively, AMOT and AMOTL2 are essential for Hippo pathway activation and appropriate cell fate specification. In the nonpolar inner cells, AMOT localizes to adherens junctions (AJs), and Ser-176 at the N-terminal domain is phosphorylated by LATS downstream of GPCR signaling, which inhibits actin binding activity and stabilizes the AMOT-LATS interaction to activate the Hippo pathway. Thus, AMOT is a direct substrate of LATS and its phosphorylation at Ser-176 inhibits cell migration and angiogenesis. In the outer cells, the cell polarity sequesters AMOT from basolateral adherens junctions to apical domains, thereby suppressing Hippo signaling.[18][19] It is therefore proposed AMOT acts as a molecular switch for Hippo pathway and links F-actin with LATS activity.[20]

Along the Hippo pathway, AMOT's binding to Merlin releases its auto-inhibition and promotes Merlin's binding to LATS1/2. Phosphorylation of Ser-518 outside the Merlin's auto-inhibitory tail prevents binding and thus inhibits Hippo pathway kinase activation.[21] USP9x regulates the ubiquitin-mediated turnover of AMOT, and the deubiquitylation of AMOT results in its stabilization and lower YAP/TAZ activity.[22]

Cancer research

[edit]

A DNA vaccination targeting angiomotin generated antibodies that detected AMOT on the endothelial cell surface, which inhibited migration. It blocked angiogenesis and prevented growth of transplanted tumors for up to 150 days in vivo. A combination of DNA vaccines encoding AMOT and the extracellular and transmembrane domains of the human EGF receptor 2 (Her-2)/neu oncogene inhibited breast cancer progression and impaired tumor vascularization in Her-2/neu transgenic mice, showing DNA vaccination targeting AMOT may be used to mimic the effect of angiostatin and no toxicity or impairment of normal blood vessels was detected.[23]

In human breast cancer tissues, AMOT is highly expressed compared with control, and its level is associated with other angiogenesis markers. AMOT links to the proliferation and invasion of breast tumours and the long-term survival of the patients, and could be a potential target for therapy.[24][25]

For melanoma, AMOT binds a variant of soluble cell adhesion molecule (sCD146) in endothelial progenitor cells (EPC). Silencing AMOT in EPC inhibits the angiogenic effect of sCD146, e.g. EPC migration, proliferation, and capacity to form capillary-like structures in Matrigel.[26]

References

[edit]
  1. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000041688 – Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ a b c Troyanovsky B, Levchenko T, Månsson G, Matvijenko O, Holmgren L (March 2001). "Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation". The Journal of Cell Biology. 152 (6): 1247–54. doi:10.1083/jcb.152.6.1247. PMC 2199208. PMID 11257124.
  5. ^ a b c Bratt A, Birot O, Sinha I, Veitonmäki N, Aase K, Ernkvist M, Holmgren L (October 2005). "Angiomotin regulates endothelial cell-cell junctions and cell motility". The Journal of Biological Chemistry. 280 (41): 34859–69. doi:10.1074/jbc.M503915200. PMID 16043488.
  6. ^ a b Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Van Meir EG, Holmgren L, Meir EG (September 2002). "Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains". Gene. 298 (1): 69–77. doi:10.1016/S0378-1119(02)00928-9. PMID 12406577.
  7. ^ "Entrez Gene: AMOT angiomotin".
  8. ^ a b Zetter BR (March 2001). "Hold that line. Angiomotin regulates endothelial cell motility". The Journal of Cell Biology. 152 (6): F35-6. doi:10.1083/jcb.152.6.F35. PMC 2199203. PMID 11257132.
  9. ^ "RCSB PDB - Gene View - AMOT - angiomotin". RCSB Protein Data Bank.
  10. ^ a b c Ernkvist M, Aase K, Ukomadu C, Wohlschlegel J, Blackman R, Veitonmäki N, Bratt A, Dutta A, Holmgren L (May 2006). "p130-angiomotin associates to actin and controls endothelial cell shape". The FEBS Journal. 273 (9): 2000–11. doi:10.1111/j.1742-4658.2006.05216.x. PMID 16640563.
  11. ^ "AMOT - Angiomotin - Homo sapiens (Human) - AMOT gene & protein". www.uniprot.org. Retrieved 2016-10-16.
  12. ^ a b Levchenko T, Aase K, Troyanovsky B, Bratt A, Holmgren L (September 2003). "Loss of responsiveness to chemotactic factors by deletion of the C-terminal protein interaction site of angiomotin". Journal of Cell Science. 116 (Pt 18): 3803–10. doi:10.1242/jcs.00694. PMID 12902404. S2CID 790463.
  13. ^ Levchenko T, Bratt A, Arbiser JL, Holmgren L (February 2004). "Angiomotin expression promotes hemangioendothelioma invasion". Oncogene. 23 (7): 1469–73. doi:10.1038/sj.onc.1207264. PMID 14730344. S2CID 2244925.
  14. ^ a b Ernkvist M, Birot O, Sinha I, Veitonmaki N, Nyström S, Aase K, Holmgren L (March 2008). "Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1783 (3): 429–37. doi:10.1016/j.bbamcr.2007.11.018. hdl:10616/39669. PMID 18164266.
  15. ^ Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL (January 2011). "Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein". Genes & Development. 25 (1): 51–63. doi:10.1101/gad.2000111. PMC 3012936. PMID 21205866.
  16. ^ Paramasivam M, Sarkeshik A, Yates JR, Fernandes MJ, McCollum D (October 2011). "Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor". Molecular Biology of the Cell. 22 (19): 3725–33. doi:10.1091/mbc.E11-04-0300. PMC 3183025. PMID 21832154.
  17. ^ Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W (March 2011). "Hippo pathway-independent restriction of TAZ and YAP by angiomotin". The Journal of Biological Chemistry. 286 (9): 7018–26. doi:10.1074/jbc.C110.212621. PMC 3044958. PMID 21224387.
  18. ^ Hirate Y, Hirahara S, Inoue K, Suzuki A, Alarcon VB, Akimoto K, Hirai T, Hara T, Adachi M, Chida K, Ohno S, Marikawa Y, Nakao K, Shimono A, Sasaki H (July 2013). "Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos". Current Biology. 23 (13): 1181–94. Bibcode:2013CBio...23.1181H. doi:10.1016/j.cub.2013.05.014. PMC 3742369. PMID 23791731.
  19. ^ Dai X, She P, Chi F, Feng Y, Liu H, Jin D, Zhao Y, Guo X, Jiang D, Guan KL, Zhong TP, Zhao B (November 2013). "Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis". The Journal of Biological Chemistry. 288 (47): 34041–51. doi:10.1074/jbc.M113.518019. PMC 3837143. PMID 24106267.
  20. ^ Hirate Y, Sasaki H (January 2014). "The role of angiomotin phosphorylation in the Hippo pathway during preimplantation mouse development". Tissue Barriers. 2 (1): e28127. doi:10.4161/tisb.28127. PMC 4022607. PMID 24843842.
  21. ^ Li Y, Zhou H, Li F, Chan SW, Lin Z, Wei Z, Yang Z, Guo F, Lim CJ, Xing W, Shen Y, Hong W, Long J, Zhang M (July 2015). "Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway". Cell Research. 25 (7): 801–17. doi:10.1038/cr.2015.69. PMC 4493278. PMID 26045165.
  22. ^ Thanh Nguyen H, Andrejeva D, Gupta R, Choudhary C, Hong X, Eichhorn PJ, Loya AC, Cohen SM (2016-03-29). "Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover". Cell Discovery. 2: 16001. doi:10.1038/celldisc.2016.1. PMC 4849470. PMID 27462448.
  23. ^ Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmäki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F, Kiessling R (June 2006). "A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth". Proceedings of the National Academy of Sciences of the United States of America. 103 (24): 9208–13. Bibcode:2006PNAS..103.9208H. doi:10.1073/pnas.0603110103. PMC 1482591. PMID 16754857.
  24. ^ Jiang WG, Watkins G, Douglas-Jones A, Holmgren L, Mansel RE (2006-01-01). "Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer". BMC Cancer. 6: 16. doi:10.1186/1471-2407-6-16. PMC 1386688. PMID 16430777.
  25. ^ Lv M, Lv M, Chen L, Qin T, Zhang X, Liu P, Yang J (April 2015). "Angiomotin promotes breast cancer cell proliferation and invasion". Oncology Reports. 33 (4): 1938–46. doi:10.3892/or.2015.3780. PMID 25647626.
  26. ^ Stalin J, Harhouri K, Hubert L, Subrini C, Lafitte D, Lissitzky JC, Elganfoud N, Robert S, Foucault-Bertaud A, Kaspi E, Sabatier F, Aurrand-Lions M, Bardin N, Holmgren L, Dignat-George F, Blot-Chabaud M (March 2013). "Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin". The Journal of Biological Chemistry. 288 (13): 8991–9000. doi:10.1074/jbc.M112.446518. PMC 3610971. PMID 23389031.

Further reading

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Angiomotin&oldid=1265097740"